- Home
- TVTX vs DNLI Comparison
TVTX vs DNLI Comparison
Compare TVTX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- DNLI
- Stock Information
- Founded
- TVTX 2008
- DNLI 2013
- Country
- TVTX United States
- DNLI United States
- Employees
- TVTX N/A
- DNLI N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TVTX Health Care
- DNLI Health Care
- Exchange
- TVTX Nasdaq
- DNLI Nasdaq
- Market Cap
- TVTX 3.1B
- DNLI 2.5B
- IPO Year
- TVTX N/A
- DNLI 2017
- Fundamental
- Price
- TVTX $35.18
- DNLI $17.42
- Analyst Decision
- TVTX Strong Buy
- DNLI Strong Buy
- Analyst Count
- TVTX 15
- DNLI 13
- Target Price
- TVTX $37.21
- DNLI $32.64
- AVG Volume (30 Days)
- TVTX 2.1M
- DNLI 1.4M
- Earning Date
- TVTX 10-30-2025
- DNLI 11-06-2025
- Dividend Yield
- TVTX N/A
- DNLI N/A
- EPS Growth
- TVTX N/A
- DNLI N/A
- EPS
- TVTX N/A
- DNLI N/A
- Revenue
- TVTX $435,826,000.00
- DNLI N/A
- Revenue This Year
- TVTX $108.68
- DNLI N/A
- Revenue Next Year
- TVTX $40.23
- DNLI $94,232.03
- P/E Ratio
- TVTX N/A
- DNLI N/A
- Revenue Growth
- TVTX 114.22
- DNLI N/A
- 52 Week Low
- TVTX $12.91
- DNLI $10.57
- 52 Week High
- TVTX $36.76
- DNLI $26.18
- Technical
- Relative Strength Index (RSI)
- TVTX 66.12
- DNLI 61.98
- Support Level
- TVTX $33.05
- DNLI $16.66
- Resistance Level
- TVTX $36.76
- DNLI $18.21
- Average True Range (ATR)
- TVTX 1.95
- DNLI 1.09
- MACD
- TVTX -0.02
- DNLI 0.17
- Stochastic Oscillator
- TVTX 80.99
- DNLI 75.56
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.